NEWS IN MULTIPLE SCLEROSIS TREATMENT
Abstract:
The therapeutic arsenal in Multiple Sclerosis (MS) has developed after the 90’s by using betainterferon,
glatiramer acetate, and then natalizumab. Currently, five oral therapies are in phase III
studies or have recently been approved for the treatment of relapsing-remitting MS: cladribine
(approved in Russia and Australia), fingolimod (approved in the US and Russia), BG-12 (phase III),
laquinimod (phase III) and teriflunomide (phase III). The new monoclonal antibodies shall innaugurate
the second generation after natalizumab.
full text article in English (.EN) |